Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26371236
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Circulation
2015 ; 132
(11
): 1038-45
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Drug Therapy for Heart Valve Diseases
#MMPMID26371236
Borer JS
; Sharma A
Circulation
2015[Sep]; 132
(11
): 1038-45
PMID26371236
show ga
Valvular heart diseases (VHDs) are progressive. When not caused by acute
comorbidities they are generally characterized by long asymptomatic phases during
which hemodynamic severity may progress leading to morbidity and mortality.
Treatment depends on VHD type and severity but when severe and symptomatic,
usually involves mechanical intervention. Asymptomatic patients, and those who
lack objective descriptors associated with high risk, are closely observed
clinically with optimization of associated cardiovascular risk factors until
surgical indications develop. Though often prescribed based on theory, no
rigorous evidence supports pharmacological therapy in most chronic situations
though drugs may be appropriate in acute valvular diseases, or as a bridge to
surgery in severely decompensated patients. Herein, we examine evidence
supporting drug use for chronic VHDs.
|Adrenergic beta-Antagonists/therapeutic use
[MESH]
|Angiotensin Receptor Antagonists/therapeutic use
[MESH]
|Angiotensin-Converting Enzyme Inhibitors/therapeutic use
[MESH]
|Animals
[MESH]
|Diphosphonates/therapeutic use
[MESH]
|Disease Models, Animal
[MESH]
|Drug Therapy/*methods/*trends
[MESH]
|Heart Valve Diseases/*drug therapy
[MESH]
|Humans
[MESH]
|Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
[MESH]
free
free
free
